Subcellular targets of cisplatin cytotoxicity: an integrated view

Pharmacol Ther. 2012 Oct;136(1):35-55. doi: 10.1016/j.pharmthera.2012.07.003. Epub 2012 Jul 14.

Abstract

Cisplatin is a chemotherapeutic drug widely used against a variety of cancers. Its clinical utility is severely limited by its toxicity, which mainly affects, but is not limited to, the inner ear and renal tubules. Cisplatin toxicity is determined by target tissue and cell accumulation, subcellular handling and trafficking through diverse subcellular structures, and interaction with macromolecules. Cisplatin accumulates and stresses different organelles from which delay signaling is activated, including mitochondria, lysosomes, the endoplasmic reticulum, the nucleus, the cell membrane and cytoskeleton, and can also be found in the cytosol. This article critically summarizes the available information in order to establish the connection among its known subcellular effects in a hierarchical and integrative framework. Cisplatin causes different types of cell death in a concentration-dependent manner. Knowledge of the events and signaling leading to the different phenotypes is also intertwined within the model, within the scope of the potential utility of this information in the improvement of the pharmacotoxicological profile of this drug. Perspectives for the key aspects that need to be addressed by future investigation are also outlined.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / toxicity*
  • Biological Transport
  • Cell Membrane / drug effects
  • Cell Nucleus / drug effects
  • Cisplatin / pharmacokinetics
  • Cisplatin / toxicity*
  • Cytoskeleton / drug effects
  • Cytosol / drug effects
  • Endoplasmic Reticulum Stress / drug effects
  • Humans
  • Lysosomes / drug effects
  • Mitochondria / drug effects

Substances

  • Antineoplastic Agents
  • Cisplatin